Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

导 ...

欧盟委员会的批准基于3期临床试验MARIPOSA的结果。该研究评估了Lazcluze联合Rybrevant，与活性对照osimertinib相比，一线治疗携带上述EGFR变异的NSCLC患者的疗效。分析显示，Rybrevant与Lazcluze联用，与活性对照药物相比，可将疾病进展或死亡风险降低30%。联合疗法与活性对照药物组患者的中位无进展生存期（PFS）分别为23.7个月与16.6个月。此外， ...

During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.

A DAILY pill that doubles survival time for lung cancer patients will be made routinely available on the NHS. Osimertinib, also known as Tagrisso and made by AstraZeneca, helps prevent cancer from ...

Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...

The European Commission (EC) has approved a Marketing Authorization (MA) for Lazcluze (lazertinib), in combination with ...

Cancer still eludes treatment, and tumors frequently evolve resistance mechanisms to get around medications. By making cancer ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) ...

Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery when taken ...